iSpecimen Inc. Deferred Revenue
iSpecimen Inc. (ISPC) had Deferred Revenue of $283.57 thousand as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:DeferredRevenueCurrent · last filed 2024-11-07
- 2024-09-30: Deferred Revenue, Current $283.57K.
- 2024-06-30: Deferred Revenue, Current $258.87K.
- 2024-03-31: Deferred Revenue, Current $272.68K.
- 2023-12-31: Deferred Revenue, Current $415.77K.
| Period end | Deferred Revenue, Current |
|---|---|
| 2024-09-30 | $283.57K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $258.87K 10-Q · filed 2024-08-06 |
| 2024-03-31 | $272.68K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $415.77K 10-Q · filed 2024-11-07 |
| 2023-09-30 | $46.91K 10-Q · filed 2023-11-02 |
| 2023-06-30 | $89.60K 10-Q · filed 2023-08-02 |
| 2023-03-31 | $97.66K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $132.34K 10-K · filed 2024-03-13 |
| 2022-06-30 | $334.98K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $567.32K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $654.75K 10-K/A · filed 2023-03-30 |
| 2021-09-30 | $718.72K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $802.86K 10-Q · filed 2021-08-10 |
| 2020-12-31 | $873.25K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |